{"id":158629,"date":"2024-02-12T06:10:58","date_gmt":"2024-02-12T11:10:58","guid":{"rendered":"https:\/\/44.250.171.167\/?p=158629"},"modified":"2024-02-12T06:10:59","modified_gmt":"2024-02-12T11:10:59","slug":"zydus-lifesciences-ltd-q3-fy24-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q3-fy24-earnings-conference-call-insights\/","title":{"rendered":"Zydus Lifesciences Ltd Q3 FY24 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q3 FY24 Earnings Concall<\/strong><\/p>\n<ul>\n<li><strong>India Formulations<\/strong>\n<ul>\n<li>Double-digit growth led by volume expansion and new launches.<\/li>\n<li>Volume growth and new product launches drove growth.<\/li>\n<li>Gained market share in key therapies; chronic portfolio grew faster than market.<\/li>\n<li>Margin expansion from better product mix and operating leverage.<\/li>\n<li>Chronic portfolio grew faster than the market at 12% vs 11% for IPM.<\/li>\n<li>Adding 700 medical representatives to expand coverage and reach<\/li>\n<\/ul>\n<\/li>\n<li><strong>US Formulations<\/strong>\n<ul>\n<li>Improved profitability from higher volumes and new product launches.<\/li>\n<li>Received approval for specialty and differentiated products.<\/li>\n<li>Well positioned to sustain growth momentum.<\/li>\n<li>Received final approval for 2 key ANDAs &#8211; Zituvio and Zituvimet.<\/li>\n<\/ul>\n<\/li>\n<li><strong>International Formulations<\/strong>\n<ul>\n<li>International business revenues grew 31% year-on-year.<\/li>\n<li>Broad based double-digit growth across regions.<\/li>\n<li>Strong demand environment in Europe and EM markets.<\/li>\n<li>Mexico business continued to grow in double digits.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Growth Plans<\/strong>\n<ul>\n<li>Continue expanding geographical reach, distribution channels, partnerships in India.<\/li>\n<li>Launch new products and leverage innovation portfolio.<\/li>\n<li>Conduct patient support programs and increase awareness of healthcare needs in India.<\/li>\n<li>In US, volume expansion in base portfolio and new launches to continue.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Innovation Pipeline Progress<\/strong>\n<ul>\n<li>Completed patient recruitment for Saroglitazar Phase 2b\/3 trials for PBC in US.<\/li>\n<li>Completed Phase 2 trial of ZY19489 potential antimalarial drug.<\/li>\n<li>2 monoclonal antibodies awaiting approval in India.<\/li>\n<li>Completed asset transfer for CUTX-101 for Menkes disease.<\/li>\n<\/ul>\n<\/li>\n<li><strong>PBC Trial Update<\/strong>\n<ul>\n<li>Completed patient enrollment for Saroglitazar Phase 2b\/3 PBC trial.<\/li>\n<li>Expecting primary endpoint data and regulatory submission by Q4 FY2025.<\/li>\n<li>52-week patient follow-up, no interim event-driven data planned.<\/li>\n<\/ul>\n<\/li>\n<li><strong>India Specialty Business<\/strong>\n<ul>\n<li>Significant growth seen for all specialty products.<\/li>\n<li>Lipaglyn expected to become largest brand for company soon.<\/li>\n<li>Large future growth opportunities seen.<\/li>\n<\/ul>\n<\/li>\n<li><strong>LiqMeds Business Outlook<\/strong>\n<ul>\n<li>Will start contributing profits immediately as existing business is profitable.<\/li>\n<li>Future growth from Zydus&#8217; expansion into UK, other markets with liquid orals portfolio.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Gross Margin Sustainability<\/strong>\n<ul>\n<li>Higher gross margins driven by product mix, new product launches in US and international markets.<\/li>\n<li>Scaling up of businesses also contributing to margin growth.<\/li>\n<li>With Revlimid relaunch gross margins expected to increase further.<\/li>\n<li>Believe current elevated margins are sustainable going forward.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Zituvio and Zituvimet Rollout<\/strong>\n<ul>\n<li>Early days, will be slow build-up of market share.<\/li>\n<li>Developing positioning with payers and customers.<\/li>\n<li>One of the important value drivers for FY25.<\/li>\n<li>Negotiations with payers ongoing, prescription ramp-up required.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Consumer Wellness\/Injectables Outlook<\/strong>\n<ul>\n<li>Skincare portfolio growing strongly, food portfolio facing challenges.<\/li>\n<li>Rural demand yet to pick up, impacting nutrition brands.<\/li>\n<li>Aiming to grow in double digits in FY24.<\/li>\n<li>Gross margins improving, new launches and distribution expansion planned.<\/li>\n<li>Gained\/maintained market share for key brands despite slow market.<\/li>\n<li>Ramp up better than previously planned targets in injectables.<\/li>\n<li>Seeing good growth opportunities from shortages, complexity.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q3 FY24 Earnings Concall India Formulations Double-digit growth led by volume expansion and new launches. Volume growth and new product launches drove growth. Gained market share in key therapies; chronic portfolio grew faster than market. Margin expansion from better product mix and operating leverage. Chronic portfolio grew faster [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":154818,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,8157,1115],"class_list":["post-158629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-healthcare","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133434,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":158629,"position":0},"title":"Zydus Lifesciences Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/R4mbpNYrIhE Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q1 FY23 Earnings Concall Q&A Highlights: Neha enquired about the drivers of strong growth in the US business QonQ and if it\u2019s sustainable. Sharvil Patel MD replied that there are no one-offs in the overall numbers. The sequential growth was due to\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170087,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q1-fy26-earnings-results\/","url_meta":{"origin":158629,"position":1},"title":"Zydus Lifesciences Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 12, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Zydus Lifesciences Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166898,"url":"https:\/\/alphastreet.com\/india\/zyduslife-q3-2024-2025-call-highlights-profit-jump-robust-margins-expansion-plans\/","url_meta":{"origin":158629,"position":2},"title":"ZYDUSLIFE Q3 2024-2025 Call Highlights: Profit Jump, Robust Margins &#038; Expansion Plans!","author":"Praveen","date":"February 17, 2025","format":false,"excerpt":"Zydus Lifesciences Ltd., a leading Indian Pharmaceutical company, in its Q3 earnings call discussed strong performance across multiple segments, with US business expecting high single-digit growth in FY26 supported by 25-30 new product launches. The company\u2019s product portfolio updates included CUTX-101, a lifelong treatment for Menkes disease, LiqMeds portfolio launches,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":172227,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q2-fy26-earnings-results\/","url_meta":{"origin":158629,"position":3},"title":"Zydus LifeSciences Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Zydus LifeSciences Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Zydus-LifeSciences-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":140022,"url":"https:\/\/alphastreet.com\/india\/zydus-lifesciences-q3fy23-net-profit-rises-by-23-revenue-soars-20\/","url_meta":{"origin":158629,"position":4},"title":"Zydus Lifesciences Q3FY23 net profit rises by 23%; Revenue soars 20%","author":"Chirag Gupta","date":"February 3, 2023","format":false,"excerpt":"Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third quarter ended December 31, 2022. The company had posted a consolidated net profit of INR 511 crore in the same period last fiscal, Zydus Lifesciences Ltd said in a regulatory\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/33edfd75-01f5-4dce-afe1-d8884b831eec.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156074,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":158629,"position":5},"title":"Aurobindo Pharma Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2023","format":false,"excerpt":"Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q2 FY24 Earnings Concall Revenue Growth Revenue grew 25.8% year-on-year to INR7,219 crores, driven by growth across formulations, APIs, and geographies. Formulations revenue, excluding Puerto Rico, grew 29% YoY to INR5,968 crores. US formulations revenue, without Puerto Rico, grew 35.7% year-on-year to INR3,385\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/158629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=158629"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/158629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/154818"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=158629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=158629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=158629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}